Frontage Holdings Corp
HKEX:1521

Watchlist Manager
Frontage Holdings Corp Logo
Frontage Holdings Corp
HKEX:1521
Watchlist
Price: 1.67 HKD 0.6% Market Closed
Market Cap: 3.4B HKD
Have any thoughts about
Frontage Holdings Corp?
Write Note

Frontage Holdings Corp
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Frontage Holdings Corp
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Frontage Holdings Corp
HKEX:1521
Accrued Liabilities
$16.9m
CAGR 3-Years
47%
CAGR 5-Years
21%
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Accrued Liabilities
$5.2B
CAGR 3-Years
9%
CAGR 5-Years
15%
CAGR 10-Years
12%
Danaher Corp
NYSE:DHR
Accrued Liabilities
$2.9B
CAGR 3-Years
-4%
CAGR 5-Years
4%
CAGR 10-Years
1%
Mettler-Toledo International Inc
NYSE:MTD
Accrued Liabilities
$364.6m
CAGR 3-Years
-4%
CAGR 5-Years
4%
CAGR 10-Years
4%
Agilent Technologies Inc
NYSE:A
Accrued Liabilities
$766m
CAGR 3-Years
-2%
CAGR 5-Years
0%
CAGR 10-Years
4%
IQVIA Holdings Inc
NYSE:IQV
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Frontage Holdings Corp
Glance View

Market Cap
3.4B HKD
Industry
Life Sciences Tools & Services

Frontage Holdings Corp. engages in the provision of research and analytical and development services throughout the drug discovery and development process. The company is headquartered in Exton, Pennsylvania. The company went IPO on 2019-05-30. Its segments include North America and the People’s Republic of China (PRC). Its North America segment, including laboratory testing, chemistry, manufacturing and control (CMC), preclinical research and chemistry services in the United States of America and Canada. Its PRC segment including laboratory testing, CMC, preclinical research, bioequivalence clinical and chemistry services in the PRC. Its preclinical research includes drug metabolism and pharmacokinetic (DMPK), safety, chemical and toxicology, and laboratory testing, including bioanalytical and biologics, and central laboratory. Its services and solutions include drug candidate evaluation, product development, clinical services and central laboratory and testing services.

Intrinsic Value
2.65 HKD
Undervaluation 37%
Intrinsic Value
Price

See Also

What is Frontage Holdings Corp's Accrued Liabilities?
Accrued Liabilities
16.9m USD

Based on the financial report for Dec 31, 2023, Frontage Holdings Corp's Accrued Liabilities amounts to 16.9m USD.

What is Frontage Holdings Corp's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
21%

Over the last year, the Accrued Liabilities growth was 36%. The average annual Accrued Liabilities growth rates for Frontage Holdings Corp have been 47% over the past three years , 21% over the past five years .

Back to Top